Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
NCT06671977
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Major Depression Disorder
- Depression
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Deepak C. D'Souza
- Last updated on ClinicalTrials.gov
- June 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.